Neurocognitive impairments in MDMA and other drug users: MDMA alone may not be a cognitive risk factor

Karen L. Hanson; Monica Luciana

doi:10.1080/13803390903042361

Neurocognitive impairments in MDMA and other drug users: MDMA alone may not be a cognitive risk factor

Karen L. Hanson, Monica Luciana

Psychology (Twin Cities)

Research output: Contribution to journal › Article › peer-review

24 Scopus citations

Abstract

Background: MDMA (3,4-methylenedioxymethamphetamine; "Ecstasy") is an amphetamine derivative with mild hallucinogenic and stimulant qualities. MDMA leads to serotonin (5-hydroxytryptamine; 5-HT) neurotoxicity and has been linked to cognitive impairments. It remains unclear whether these impairments are due to MDMA versus other drug use. Method: Neurocognitive functioning was measured in a sample of abstinent polydrug users (n = 52) with a range of MDMA use and healthy nondrug controls (n = 29). Participants completed a comprehensive neuropsychological battery and self-report measures of drug use. Results: Polydrug users performed worse than controls on spatial span and spatial working memory (ps < .05). Among polydrug users, lifetime marijuana use significantly predicted verbal learning and memory performance (p < .01), while MDMA use was not predictive of cognitive impairment. Conclusions: This study and our previous report (Hanson, Luciana, & Sullwold, 2008) suggest that moderate MDMA use does not lead to persistent impairments above and beyond that associated with generally heavy drug use, but polydrug use may lead to dose-related temporal and frontoparietal dysfunction. Marijuana use may be particularly problematic. Cause-effect relations are unclear.

Original language	English (US)
Pages (from-to)	337-349
Number of pages	13
Journal	Journal of Clinical and Experimental Neuropsychology
Volume	32
Issue number	4
DOIs	https://doi.org/10.1080/13803390903042361
State	Published - Apr 2010

Bibliographical note

Funding Information:
This project was supported by the University of Minnesota Graduate School Doctoral Dissertation Research Grant, the National Institute of Mental Health (NIMH) Neurobehavioral Aspects of Personality & Psychopathology T32 Pre-Doctoral Traineeship at the University of Minnesota Department of Psychology, and the National Institute on Alcohol Abuse and Alcoholism (NIAAA) Alcohol Research in the Science/Practitioner Model T32 Post-Doctoral Fellowship at San Diego State University awarded to Karen L. Hanson and by the McKnight Land-Grant Professorship awarded to Monica Luciana by the Office of the Vice President for Research at the University of Minnesota. We would like to thank David Ansari, Danielle Cheek, Patricia Dickmann, Catalina Hooper, Melissa Saari, Athenais Snaza, Kristin Sullwold, and Dustin Wahlstrom for their assistance with data collection and management.

Copyright:
Copyright 2010 Elsevier B.V., All rights reserved.

Keywords

3,4-Methylenedioxymethamphetamine
Cognition
Drug use
Ecstasy
Executive function
Marijuana
Memory
Serotonin

Publisher link

10.1080/13803390903042361

Find It

Find It at U of M Libraries

Cite this

@article{0b21910128a64ed98ea0f51efa1692a2,

title = "Neurocognitive impairments in MDMA and other drug users: MDMA alone may not be a cognitive risk factor",

abstract = "Background: MDMA (3,4-methylenedioxymethamphetamine; {"}Ecstasy{"}) is an amphetamine derivative with mild hallucinogenic and stimulant qualities. MDMA leads to serotonin (5-hydroxytryptamine; 5-HT) neurotoxicity and has been linked to cognitive impairments. It remains unclear whether these impairments are due to MDMA versus other drug use. Method: Neurocognitive functioning was measured in a sample of abstinent polydrug users (n = 52) with a range of MDMA use and healthy nondrug controls (n = 29). Participants completed a comprehensive neuropsychological battery and self-report measures of drug use. Results: Polydrug users performed worse than controls on spatial span and spatial working memory (ps < .05). Among polydrug users, lifetime marijuana use significantly predicted verbal learning and memory performance (p < .01), while MDMA use was not predictive of cognitive impairment. Conclusions: This study and our previous report (Hanson, Luciana, & Sullwold, 2008) suggest that moderate MDMA use does not lead to persistent impairments above and beyond that associated with generally heavy drug use, but polydrug use may lead to dose-related temporal and frontoparietal dysfunction. Marijuana use may be particularly problematic. Cause-effect relations are unclear.",

keywords = "3,4-Methylenedioxymethamphetamine, Cognition, Drug use, Ecstasy, Executive function, Marijuana, Memory, Serotonin",

author = "Hanson, {Karen L.} and Monica Luciana",

note = "Funding Information: This project was supported by the University of Minnesota Graduate School Doctoral Dissertation Research Grant, the National Institute of Mental Health (NIMH) Neurobehavioral Aspects of Personality & Psychopathology T32 Pre-Doctoral Traineeship at the University of Minnesota Department of Psychology, and the National Institute on Alcohol Abuse and Alcoholism (NIAAA) Alcohol Research in the Science/Practitioner Model T32 Post-Doctoral Fellowship at San Diego State University awarded to Karen L. Hanson and by the McKnight Land-Grant Professorship awarded to Monica Luciana by the Office of the Vice President for Research at the University of Minnesota. We would like to thank David Ansari, Danielle Cheek, Patricia Dickmann, Catalina Hooper, Melissa Saari, Athenais Snaza, Kristin Sullwold, and Dustin Wahlstrom for their assistance with data collection and management. Copyright: Copyright 2010 Elsevier B.V., All rights reserved.",

year = "2010",

month = apr,

doi = "10.1080/13803390903042361",

language = "English (US)",

volume = "32",

pages = "337--349",

journal = "Journal of Clinical and Experimental Neuropsychology",

issn = "1380-3395",

publisher = "Taylor and Francis Ltd.",

number = "4",

}

TY - JOUR

T1 - Neurocognitive impairments in MDMA and other drug users

T2 - MDMA alone may not be a cognitive risk factor

AU - Hanson, Karen L.

AU - Luciana, Monica

N1 - Funding Information: This project was supported by the University of Minnesota Graduate School Doctoral Dissertation Research Grant, the National Institute of Mental Health (NIMH) Neurobehavioral Aspects of Personality & Psychopathology T32 Pre-Doctoral Traineeship at the University of Minnesota Department of Psychology, and the National Institute on Alcohol Abuse and Alcoholism (NIAAA) Alcohol Research in the Science/Practitioner Model T32 Post-Doctoral Fellowship at San Diego State University awarded to Karen L. Hanson and by the McKnight Land-Grant Professorship awarded to Monica Luciana by the Office of the Vice President for Research at the University of Minnesota. We would like to thank David Ansari, Danielle Cheek, Patricia Dickmann, Catalina Hooper, Melissa Saari, Athenais Snaza, Kristin Sullwold, and Dustin Wahlstrom for their assistance with data collection and management. Copyright: Copyright 2010 Elsevier B.V., All rights reserved.

PY - 2010/4

Y1 - 2010/4

N2 - Background: MDMA (3,4-methylenedioxymethamphetamine; "Ecstasy") is an amphetamine derivative with mild hallucinogenic and stimulant qualities. MDMA leads to serotonin (5-hydroxytryptamine; 5-HT) neurotoxicity and has been linked to cognitive impairments. It remains unclear whether these impairments are due to MDMA versus other drug use. Method: Neurocognitive functioning was measured in a sample of abstinent polydrug users (n = 52) with a range of MDMA use and healthy nondrug controls (n = 29). Participants completed a comprehensive neuropsychological battery and self-report measures of drug use. Results: Polydrug users performed worse than controls on spatial span and spatial working memory (ps < .05). Among polydrug users, lifetime marijuana use significantly predicted verbal learning and memory performance (p < .01), while MDMA use was not predictive of cognitive impairment. Conclusions: This study and our previous report (Hanson, Luciana, & Sullwold, 2008) suggest that moderate MDMA use does not lead to persistent impairments above and beyond that associated with generally heavy drug use, but polydrug use may lead to dose-related temporal and frontoparietal dysfunction. Marijuana use may be particularly problematic. Cause-effect relations are unclear.

AB - Background: MDMA (3,4-methylenedioxymethamphetamine; "Ecstasy") is an amphetamine derivative with mild hallucinogenic and stimulant qualities. MDMA leads to serotonin (5-hydroxytryptamine; 5-HT) neurotoxicity and has been linked to cognitive impairments. It remains unclear whether these impairments are due to MDMA versus other drug use. Method: Neurocognitive functioning was measured in a sample of abstinent polydrug users (n = 52) with a range of MDMA use and healthy nondrug controls (n = 29). Participants completed a comprehensive neuropsychological battery and self-report measures of drug use. Results: Polydrug users performed worse than controls on spatial span and spatial working memory (ps < .05). Among polydrug users, lifetime marijuana use significantly predicted verbal learning and memory performance (p < .01), while MDMA use was not predictive of cognitive impairment. Conclusions: This study and our previous report (Hanson, Luciana, & Sullwold, 2008) suggest that moderate MDMA use does not lead to persistent impairments above and beyond that associated with generally heavy drug use, but polydrug use may lead to dose-related temporal and frontoparietal dysfunction. Marijuana use may be particularly problematic. Cause-effect relations are unclear.

KW - 3,4-Methylenedioxymethamphetamine

KW - Cognition

KW - Drug use

KW - Ecstasy

KW - Executive function

KW - Marijuana

KW - Memory

KW - Serotonin

UR - http://www.scopus.com/inward/record.url?scp=77951227430&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951227430&partnerID=8YFLogxK

U2 - 10.1080/13803390903042361

DO - 10.1080/13803390903042361

M3 - Article

C2 - 20397296

AN - SCOPUS:77951227430

SN - 1380-3395

VL - 32

SP - 337

EP - 349

JO - Journal of Clinical and Experimental Neuropsychology

JF - Journal of Clinical and Experimental Neuropsychology

IS - 4

ER -

Neurocognitive impairments in MDMA and other drug users: MDMA alone may not be a cognitive risk factor

Abstract

Bibliographical note

Keywords

Publisher link

Find It

Other files and links

Fingerprint

Cite this